- Ashland completed the second expansion of its pharmaceutical injectables manufacturing and R&D lab in Mullingar, Ireland.
- The expansion was completed as scheduled and will be celebrated on August 22, 2024.
- The project is supported by the Irish Government through IDA Ireland.
- Ashland supplies over 70 GMP grades of lactide/glycolide/caprolactone copolymers within its Viatel™ portfolio.
Expansion Completion
Ashland has completed the second expansion of its pharmaceutical injectables manufacturing and R&D lab at the National Science Park in Mullingar, Ireland. The expansion was completed as scheduled and will be celebrated with a ribbon-cutting ceremony on August 22, 2024.
Project Support
This project is supported by the Irish Government through IDA Ireland. Peter Burke, Ireland's minister for enterprise trade and employment, highlighted the investment's significance for the Midlands region and its role in strengthening Ireland's position in the life sciences sector.
Technological Advancements
The expansion significantly enhances Ashland’s capabilities and headcount at the Irish facility, focusing on innovative bioresorbable polymer chemistry to meet increasing market demand. These polymers are crucial for developing improved pharmaceuticals, medical devices, and tissue engineering solutions.
Product Portfolio
Ashland supplies over 70 GMP grades of lactide/glycolide/caprolactone copolymers within its growing Viatel™ portfolio and offers custom-made and ultrapure polymer production options. The company is accelerating the delivery of cutting-edge chemistry to meet growing customer requirements for both existing and new polymers.
Local Talent and Collaboration
The expansion underscores Ashland’s commitment to Ireland and highlights the importance of collaboration for site and technology development. The company aims to leverage local talent from the nearby Technological University of the Shannon (TUS) to support its growth and innovation efforts.
